Ciba-geigy Corporation

Novartis Corporation

Ucp Gen-pharma Ag

Walter Marki

Hans Rink

Bernd Meyhack

Markus G Grutter

Albert Schmitz

Manfred Liersch

Jui Y Chang

Hugo Grossenbacher

The invention relates to DNA sequences that code for the amino acid sequence of the thrombin inhibitor hirudin, hybrid vectors containing such DNA sequences, host cells transformed with such hybrid vectors, novel polypeptides with thrombin-inhibiting activity produced from such transformed host cells, processes for the manufacture of these DNA sequences, hybrid vectors and transformed host cells, and processes for the manufacture of these thrombin-inhibitors using the transformed host cells. The hirudin compounds that can be produced according to the invention have valuable pharmacological properties.

Process for the manufacture of thrombin inhibitors

A process for the preparation of a recombinant IGF-II (rIGF-II) without a covalently attached foreign protein moiety and without N-terminal attached methionine or a derivative of methionine or of a salt of said IGF-II, rIGF-II produced by said method, hybrid vectors comprising DNA encoding said rIGF-II, hosts transformed with said vectors, and a process for the isolation of said rIGF-II from the host cell and refolding it into a biologically active form.

Process for the production and refolding of unfused IGF-II protein in E.

High molecular weight desulphatohirudin

Process for the production of unfused IGF-II protein in E. coli

Growing community of inventors

Mohlin, Switzerland

Walter Marki